Side Effects of Lynkuet (Elinzanetant)
The most common side effects of Lynkuet (elinzanetant) are headache, fatigue, and somnolence, which are generally mild and manageable, with no evidence of serious hepatotoxicity, endometrial hyperplasia, or clinically significant bone density changes in clinical trials. 1, 2
Most Frequent Adverse Events
Common Side Effects (Weeks 1-12)
- Headache is among the most frequently reported adverse events 1, 2
- Fatigue occurs commonly and is typically mild 1, 2
- Somnolence (drowsiness) is reported frequently, though next-morning residual effects on driving performance are not clinically significant 1, 3
During the first 12 weeks of treatment, approximately 69.8% of patients receiving elinzanetant reported at least one adverse event in the OASIS-4 trial, compared to 62.0% receiving placebo 1. Treatment-related adverse events occurred in 30.4% of elinzanetant patients versus 14.6% of placebo patients in the OASIS-3 trial 2.
Serious Adverse Events
Serious adverse events are uncommon, occurring in only 2.5% of patients during weeks 1-12 in the OASIS-4 trial 1. The OASIS-3 trial demonstrated no serious safety concerns over 52 weeks of treatment 2.
Organ-Specific Safety Profile
Hepatic Safety
- No evidence of drug-related hepatotoxicity has been observed in clinical trials 2, 4
- Elinzanetant was not associated with hepatotoxic effects in the 52-week OASIS-3 study 2
Endometrial Safety
- No endometrial hyperplasia was detected during clinical trials 2
Bone Health
- No meaningful changes in bone density or bone turnover markers were observed 2
Central Nervous System Effects
- Small increases in standard deviation of lateral position (SDLP) during simulated driving were observed on Day 2 but not on Day 6, indicating no clinically relevant next-morning residual effects 3
- The benefit-risk balance is not adversely impacted by somnolence or fatigue the following morning 3
Dose-Related Considerations
Higher doses are associated with increased adverse effects 5. The 120 mg daily dose demonstrated good efficacy with an acceptable safety profile and was selected for Phase III trials 4, 6. The 240 mg dose did not show an increase in adverse event frequency compared to the 120 mg dose in driving performance studies 3.
Comparative Safety Profile
Elinzanetant demonstrates a more favorable side-effect profile compared to fezolinetant (another neurokinin receptor antagonist) in meta-analyses 5. The drug is generally well-tolerated with no serious adverse events reported in Phase IIb trials 4.
Key Clinical Pitfalls to Avoid
- Do not discontinue therapy prematurely for mild somnolence or fatigue, as these effects may diminish with continued use 3
- Monitor for headache, fatigue, and somnolence particularly during treatment initiation 1, 2
- Reassure patients that next-morning driving ability is not clinically impaired despite potential somnolence 3